fluvastatin
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aortic Valve Stenosis
Conditions
Aortic Valve Stenosis
Trial Timeline
Jan 1, 2003 → Dec 1, 2009
NCT ID
NCT00176410About fluvastatin
fluvastatin is a phase 2 stage product being developed by Novartis for Aortic Valve Stenosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00176410. Target conditions include Aortic Valve Stenosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01045512 | Phase 2 | Terminated |
| NCT00136799 | Phase 3 | Completed |
| NCT00125125 | Approved | Completed |
| NCT00138528 | Approved | Completed |
| NCT00171262 | Approved | Completed |
| NCT00171275 | Approved | Completed |
| NCT00176410 | Phase 2 | UNKNOWN |
| NCT00171236 | Phase 3 | Completed |
| NCT00565474 | Approved | Completed |
Competing Products
20 competing products in Aortic Valve Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 72 |
| Edoxaban | Daiichi Sankyo | Phase 3 | 77 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 85 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 52 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| candesartan + placebo | AstraZeneca | Phase 3 | 77 |
| Sugammadex | Merck | Approved | 85 |
| bisoprolol + placebo | Merck | Approved | 85 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 65 |
| Pelacarsen (TQJ230) 80mg + Matching placebo | Novartis | Phase 2 | 52 |
| ACZ885 + Placebo | Novartis | Phase 2 | 52 |
| Evolocumab + Placebo | Amgen | Phase 1 | 32 |
| atorvastatin (Lipitor) | Pfizer | Approved | 84 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 32 |
| Ataciguat (HMR1766) | Sanofi | Phase 2 | 51 |
| Haemocomplettan® P + Saline solution | CSL | Phase 2 | 51 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 74 |
| Acetylsalicylic acid + Clopidogrel + Rivaroxaban | Bayer | Phase 3 | 74 |
| Desflurane | Baxter | Approved | 82 |